RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors It is sad it potentially could have helped, and I wonder if anyone else in her situation has been put through the program with ovarian cancer and seen any benefit. There is not much explained thus far, but Soleus did top up at the financing. It makes me wonder if they had access to more data than we have, and if so, hmmm.
juniper88 wrote: The biomarker for ovarian cancer is CA-125.
With my wife after 1 infusion of TH1902 it dropped by over 40%. I remember Dr. Winers assistant coming back to us with a smile. We were very happy. But my wife had 2 stents placed in her liver and pancreas. They became infected and that is why she died. Also because so much time was wasted and she had become so weak. We'll never know how well it would have worked for her.